162997-46-8

Basic information

• Product Name: 4-[4-(Hydroxymethyl)piperidin-1-yl]benzonitrile
• Synonyms: 4-[4-(Hydroxymethyl)piperidin-1-yl]benzonitrile
• CAS NO: 162997-46-8
• Molecular Formula: C₁₃H₁₆N₂O
• Molecular Weight: 216.27894
• Mol File: 162997-46-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 149-151
• Boiling Point: 415.5±20.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• PKA: 14.94±0.10(Predicted)
• CAS DataBase Reference: 4-[4-(Hydroxymethyl)piperidin-1-yl]benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(Hydroxymethyl)piperidin-1-yl]benzonitrile(162997-46-8)
• EPA Substance Registry System: 4-[4-(Hydroxymethyl)piperidin-1-yl]benzonitrile(162997-46-8)

Safety Data

• Hazardous Substances Data: 162997-46-8(Hazardous Substances Data)

Upstream product

• 6457-49-4 4-piperidinemethanol 
• 1194-02-1 4-fluorobenzonitrile 
• 90748-01-9 4-piperidinemethanol hydrochloride 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 

Downstream Products

• 162997-47-9 1-(4-cyanophenyl)-4-mesyloxymethyl-piperidine 
• 861210-09-5 C₁₃H₂₀N₂O 
• 1334720-22-7 6-chloro-2-ethyl-N-(4-(4-((4-(trifluoromethoxy)phenoxy)methyl)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION

The present invention provides compounds of Formula I: wherein Y, AA, W, R3, R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to carboxylic acid derivatives of general formula wherein A to G are defined as in claim 1, the tautomers thereof, the stereoisomers thereof including the mixtures thereof and the addition salts thereof, particularly the physiologically acceptable salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably inhibitory effects on aggregation, and to pharmaceutical compositions containing the compounds and processes for preparing them.